Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers.

Hydbring P, Wang Y, Fassl A, Li X, Matia V, Otto T, Choi YJ, Sweeney KE, Suski JM, Yin H, Bogorad RL, Goel S, Yuzugullu H, Kauffman KJ, Yang J, Jin C, Li Y, Floris D, Swanson R, Ng K, Sicinska E, Anders L, Zhao JJ, Polyak K, Anderson DG, Li C, Sicinski P.

Cancer Cell. 2017 Apr 10;31(4):576-590.e8. doi: 10.1016/j.ccell.2017.03.004.

PMID:
28399412
2.

NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways.

Yuzugullu H, Von T, Thorpe LM, Walker SR, Roberts TM, Frank DA, Zhao JJ.

Cell Discov. 2016 Sep 20;2:16030. doi: 10.1038/celldisc.2016.30. eCollection 2016.

3.

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.

Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, Ramm S, Palmer AC, Yuzugullu H, Varadan V, Tuck D, Harris LN, Wong KK, Liu XS, Sicinski P, Winer EP, Krop IE, Zhao JJ.

Cancer Cell. 2016 Mar 14;29(3):255-69. doi: 10.1016/j.ccell.2016.02.006.

4.

A PI3K p110β-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis.

Yuzugullu H, Baitsch L, Von T, Steiner A, Tong H, Ni J, Clayton LK, Bronson R, Roberts TM, Gritsman K, Zhao JJ.

Nat Commun. 2015 Oct 7;6:8501. doi: 10.1038/ncomms9501.

5.

CDK7-dependent transcriptional addiction in triple-negative breast cancer.

Wang Y, Zhang T, Kwiatkowski N, Abraham BJ, Lee TI, Xie S, Yuzugullu H, Von T, Li H, Lin Z, Stover DG, Lim E, Wang ZC, Iglehart JD, Young RA, Gray NS, Zhao JJ.

Cell. 2015 Sep 24;163(1):174-86. doi: 10.1016/j.cell.2015.08.063.

6.

PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.

Thorpe LM, Yuzugullu H, Zhao JJ.

Nat Rev Cancer. 2015 Jan;15(1):7-24. doi: 10.1038/nrc3860. Review.

7.

Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.

Gritsman K, Yuzugullu H, Von T, Yan H, Clayton L, Fritsch C, Maira SM, Hollingworth G, Choi C, Khandan T, Paktinat M, Okabe RO, Roberts TM, Zhao JJ.

J Clin Invest. 2014 Apr;124(4):1794-809. doi: 10.1172/JCI69927. Epub 2014 Feb 24.

8.

Genome-wide transcriptional reorganization associated with senescence-to-immortality switch during human hepatocellular carcinogenesis.

Yildiz G, Arslan-Ergul A, Bagislar S, Konu O, Yuzugullu H, Gursoy-Yuzugullu O, Ozturk N, Ozen C, Ozdag H, Erdal E, Karademir S, Sagol O, Mizrak D, Bozkaya H, Ilk HG, Ilk O, Bilen B, Cetin-Atalay R, Akar N, Ozturk M.

PLoS One. 2013 May 15;8(5):e64016. doi: 10.1371/journal.pone.0064016. Print 2013.

9.

Aflatoxin genotoxicity is associated with a defective DNA damage response bypassing p53 activation.

Gursoy-Yuzugullu O, Yuzugullu H, Yilmaz M, Ozturk M.

Liver Int. 2011 Apr;31(4):561-71. doi: 10.1111/j.1478-3231.2011.02474.x. Epub 2011 Feb 15.

PMID:
21382167
10.

The ability to generate senescent progeny as a mechanism underlying breast cancer cell heterogeneity.

Mumcuoglu M, Bagislar S, Yuzugullu H, Alotaibi H, Senturk S, Telkoparan P, Gur-Dedeoglu B, Cingoz B, Bozkurt B, Tazebay UH, Yulug IG, Akcali KC, Ozturk M.

PLoS One. 2010 Jun 24;5(6):e11288. doi: 10.1371/journal.pone.0011288.

11.

Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells.

Yuzugullu H, Benhaj K, Ozturk N, Senturk S, Celik E, Toylu A, Tasdemir N, Yilmaz M, Erdal E, Akcali KC, Atabey N, Ozturk M.

Mol Cancer. 2009 Oct 22;8:90. doi: 10.1186/1476-4598-8-90.

12.

Senescence and immortality in hepatocellular carcinoma.

Ozturk M, Arslan-Ergul A, Bagislar S, Senturk S, Yuzugullu H.

Cancer Lett. 2009 Dec 1;286(1):103-13. doi: 10.1016/j.canlet.2008.10.048. Epub 2008 Dec 12. Review.

PMID:
19070423

Supplemental Content

Loading ...
Support Center